ORIGINAL RESEARCH article
Front. Public Health
Sec. Children and Health
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1632250
This article is part of the Research TopicPrenatal Environmental and Genetic Interactions: An Exploration from Fetal Development to Child HealthView all 11 articles
Down syndrome burden in China and globally: a comparative analysis of 1990-2021 trends and future projections based on GBD 2021 database
Provisionally accepted
- 1Ganzhou Women and Children' hospital, Ganzhou, China
- 2Ganzhou Center for Disease Control and Prevention, Ganzhou, Jiangxi Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Down syndrome (DS), a neurodevelopmental disorder caused by a chromosomal abnormality, poses a major burden on global health. Analyzing the disease burden of DS, both in China and globally, is crucial for refining public health strategies.Using the Global Burden of Disease (GBD) 2021 database, we examined age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized disability-adjusted life year rate (ASDR) for DS in China and globally from 1990 to 2021. Joinpointregression analysis was applied to identify temporal trends by calculating the annual percent change (APC) and average annual percent change (AAPC). A bayesian age-period-cohort (BAPC) model was further employed to project prevalence changes from 2022 to 2036.From 1990 to 2021, China's ASIR decreased from 1.68 per 100,000 to 1.18 per 100,000, compared to a global reduction from 1.27 per 100,000 to 0.97 per 100,000. Similarly, ASPR in China fell from 28.01 per 100,000 to 24.8 per 100,000, while globally it dropped from 27.98 per 100,000 to 21.07 per 100,000. Notably, China experienced steeper declines in ASMR (EAPC = -4.18%) and ASDR (EAPC = -3.87%) compared to the global averages (-0.44% and -0.69%, respectively).Joinpoint regression analysis shows that from 1990 to 2021, China's ASIR (AAPC = -1.15, P < 0.001), ASPR (AAPC = -0.39, P < 0.001), ASDR (AAPC = -2.87, P < 0.001), and ASMR (AAPC = -3.08, P < 0.001) for DS all decreased. The SDI was negatively correlated with ASMR (R= -0.68, P < 0.001) and ASDR (R= -0.66, P < 0.001) but positively associated with ASIR (R= 0.55, P < 0.001) and ASPR (R= 0.80, P < 0.001). Projections from the BAPC model suggest that the ASPR of DS will continue to decline both in China and globally through 2036.From 1990 to 2021, the disease burden of DS declined in China and globally. China's decline in ASMR and ASDR outpaced the global level, though ASIR and ASPR remained higher. To further reduce DS burden, future efforts should prioritize early identification, counseling for informed decision-making, and equitable access to quality lifelong multidisciplinary support for affected individuals.
Keywords: Bayesian age-period-cohort model, Down Syndrome, Global disease burden, Joinpoint regression, socio-demographic index
Received: 20 May 2025; Accepted: 28 Jul 2025.
Copyright: © 2025 Tu, Zhang, Chen and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Manmei Tang, Ganzhou Center for Disease Control and Prevention, Ganzhou, 341000, Jiangxi Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.